Role of aminoguanidine in brain protection in surgical brain injury in rat.
The study investigated the effect of aminoguanidine (AG) on surgical brain injury (SBI) in rat. AG (75, 150 and 300 mg/kg, i.p.) was administered immediately following surgical resection. Using a SBI model, we found that AG (150 mg/kg) significantly reduced cerebral edema, while AG at the doses of 75 and 300 mg/kg had no effect. And AG (150 mg/kg) significantly reduced Evans Blue extravasation into brain tissue and improved the neurological outcome compared to control group. Moreover, the expression of TNF-alpha and nuclear factor-kappaB (NF-kappaB) mRNA and protein in brain tissue at the edge of the resection site increased at 24h after SBI, which could be significantly attenuated by the treatment with AG via RT-PCR and Western blots methods. Our results demonstrated that SBI causes increased brain edema, BBB disruption and inflammation along the periphery of the site of surgical resection, which could be significantly improved by the treatment of AG.
Di
Fan
F
Department of Neurosurgery, The General Hospital of Shenyang Military Region, Shen yang 110016, Liaoning Province, PR China.
Yan-Ting
Gu
G
Hui
Lv
L
Tao
Tang
T
Zai-Hua
Xu
X
Xue-Ying
Shi
S
Hong-Li
Xue
X
Yun-Jie
Wang
W
D000818:Animals; D001812:Blood-Brain Barrier / Q000187:drug effects / Q000503:physiopathology; D015153:Blotting, Western; D001921:Brain / Q000187:drug effects / Q000378:metabolism / Q000601:surgery*; D001923:Brain Chemistry / Q000187:drug effects; D001929:Brain Edema / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D001930:Brain Injuries / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D004660:Encephalitis / Q000188:drug therapy; D005070:Evans Blue; D005119:Extravasation of Diagnostic and Therapeutic Materials; D006146:Guanidines / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D016328:NF-kappa B / Q000378:metabolism; D018696:Neuroprotective Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D012333:RNA, Messenger / Q000378:metabolism; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D006146:Guanidines; D016328:NF-kappa B; D018696:Neuroprotective Agents; D012333:RNA, Messenger; D014409:Tumor Necrosis Factor-alpha; D005070:Evans Blue; C004479:pimagedine